1158PPhase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; no. suppl_8
Main Authors Drescher, C, Moore, K N, Liu, J F, O'Malley, D M, Wang, E W, Wang, J S-Z, Subbiah, V, Wilky, B A, Yuan, G, Dupont, C D, Gonzalez, A M, Savitsky, D, Coulter, S, Shebanova, O, Dow, E, Ortuzar, W, Buell, J S, Stein, R B, Youssoufian, H
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy288.031